Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02502071 · ClinicalTrials.gov registry record · Phase 4
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
A Phase 4 study of Type 1 Diabetes and Diabetic Kidney Disease, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT02502071: Completed Phase 4 study of Type 1 Diabetes and Diabetic Kidney Disease, sponsored by University of Colorado, Denver.
NCT02502071 is a Phase 4 study of Type 1 Diabetes and Diabetic Kidney Disease that has completed, run by University of Colorado, Denver. The registered enrollment target is 45 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02502071, a Phase 4 study of Type 1 Diabetes and Diabetic Kidney Disease, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether alkalinization of urine uric acid by 2 doses of sodium bicarbonate (1950mg) over 24-hours reduces precipitation and crystallization of urine uric acid over in adults with type 1 diabetes.
Primary Outcome
Urine uric acid were evaluated using a QuantiChrom UA kit assay (DIUA-250) with quantitative colorimetric UA determination at 590 nm (BioAssay System, California, USA).
Conditions Studied
Interventions
- DRUG sodium bicarbonate
Study Locations (1)
Colorado
- Barbara Davis Center for Diabetes - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-08 |
| Phase | Phase 4 |
What the finished NCT02502071 record still lists
NCT02502071 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which sodium bicarbonate is the first listed.
NCT02502071 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT02502071 about?
NCT02502071 is a clinical study titled "Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes". The purpose of this study is to determine whether alkalinization of urine uric acid by 2 doses of sodium bicarbonate (1950mg) over 24-hours reduces precipitation and crystallization of urine uric acid over in adults with type 1 diabetes.
What is the current status of trial NCT02502071?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2017-01. Estimated completion is 2017-08.
What conditions does trial NCT02502071 study?
This clinical trial studies the following conditions: Type 1 Diabetes, Diabetic Kidney Disease, Diabetic Nephropathy.
What interventions are being tested in trial NCT02502071?
The interventions under investigation include: sodium bicarbonate (DRUG).
Who is sponsoring clinical trial NCT02502071?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02502071 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02502071's enrollment target sits among peer trials
45 97th of 198 higher than 100 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extended Bolus for Meals in a Closed-loop System
RECRUITING · Phase 4
-
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
RECRUITING · Phase 4
-
Diabetes in African Youth
RECRUITING · Phase 4
-
Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose
COMPLETED · Phase 4
-
Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes
COMPLETED · Phase 4
-
Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia